Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

• Klaus Geissler,
• Eva Jäger,
• Agnes Barna,
• Thamer Sliwa,
• Paul Knöbl,
• Ilse Schwarzinger,
• Heinz Gisslinger,
• Peter Valent

Affiliations

Klaus Geissler

5th Medical Department with Hematology, Oncology and Palliative Medicine, Hospital Hietzing, Vienna, Austria

Eva Jäger

Department of Laboratory Medicine, Medical University of Vienna, Austria

Agnes Barna

Blood Transfusion Service for Upper Austria, Austrian Red Cross, Linz, Austria

Thamer Sliwa

3rd Medical Department, Hanusch Hospital, Vienna, Austria

Paul Knöbl

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria

Ilse Schwarzinger

Department of Laboratory Medicine, Medical University of Vienna, Austria

Heinz Gisslinger

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria

Peter Valent

Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Austria